Lacutamab (formerly IPH4102) is an investigational, first-in-class humanized monoclonal antibody that targets KIR3DL2, an inhibitory receptor belonging to the killer cell immunoglobulin-like receptor (KIR) family. KIR3DL2 is selectively and highly expressed on the malignant T cells in certain cutaneous T-cell lymphomas (CTCL), particularly Sézary syndrome and mycosis fungoides. By binding to KIR3DL2, Lacutamab is designed to induce antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), leading to the targeted elimination of the malignant T cells. It represents a promising tumor-selective immunotherapy for these rare and aggressive lymphomas.